SGLT-2 Therapy Center

The different mechanisms of action of these two drugs make them an excellent combination in the treatment of patients with type 2 diabetes mellitus (T2DM).

Sotagliflozin to be reviewed by the FDA as possible oral adjunct for people with insulin-treated type 1 diabetes.

Detection of euglycemic ketoacidosis could be a challenge for physicians since this condition can mask an underlying diabetic ketoacidosis.

2016 FDA warning conflicts with recent evidence showing no increased risk following use of treatment.

Benefits of SGLT2 inhibitors in patients treated with insulin.

First real-world study comparing SGLT2i therapies also showed patients taking INVOKANA 300 mg significantly less likely to discontinue treatment or switch to another diabetes medicine.

SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors compared in reducing mortality and cardiovascular events in patients with type 2.

Treatment method reduced the amount of liver fat more than standard treatment alone.

Surprise findings for treatment class and appropriate patient selection

Why and when to use this therapy to treat patients who have type 2 diabetes.